CTLA4 and amyotrophic lateral sclerosis: In the present open-label study, we evaluate the safety and tolerability of CTLA4-Ig together with subcutaneous low-dose IL-2 administration in four participants with ALS and monitor biological markers of oxidative stress (oxidized-LDL and 4-HNE), proinflammatory cytokine release (IL-18), and the cytoskeletal component (Nf-L).